Novo Nordisk's FREHEMGO Secures CHMP Backing for EU Approval in Haemophilia A
NVO sits 22% above its 52-week low of $35.12.
Summary
CHMP recommended EU approval of FREHEMGO (denecimig) for haemophilia A, with launch expected in Q4 2026. The drug offers flexible monthly, biweekly and weekly dosing in a pre-filled pen.
Key Events · Product Development and Regulatory · NVO
-
CHMP Recommends EU Approval
CHMP adopted a positive opinion recommending marketing authorisation for FREHEMGO (denecimig) to treat haemophilia A, with or without inhibitors, in adults and children.
-
First-in-Class Dosing Flexibility
FREHEMGO is the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks and once-weekly prophylaxis in a single-use pre-filled pen.
-
EU Launch Timeline
Novo expects to launch FREHEMGO in the first European countries in Q4 2026 and broadly across the EU starting early 2027.
-
FRONTIER Efficacy and Safety
Across the FRONTIER programme, denecimig showed mean annualised bleeding rates generally below 1, with a substantial proportion of participants experiencing zero treated bleeds; FRONTIER 5 found no new safety signals when switching directly from emicizumab.
Analysis · NVO · Life Sciences
A positive CHMP opinion clears the path for EU marketing authorisation of FREHEMGO (denecimig), Novo's next-generation FVIIIa mimetic for haemophilia A. The drug is the first in its class to offer once-monthly, once-every-two-weeks and once-weekly prophylaxis in a pre-filled pen, a dosing flexibility that could meaningfully differentiate it from Roche's emicizumab (Hemlibra). Launch in the first European countries is expected in Q4 2026, with a broader EU rollout starting early 2027. The FRONTIER programme showed annualised bleeding rates generally below 1 and a substantial proportion of patients with zero treated bleeds, with no new safety signals when switching directly from emicizumab. This is a meaningful commercial catalyst for Novo's rare disease franchise, which has been overshadowed by the GLP-1 portfolio.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVO was trading at $42.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $184.8B. The 52-week trading range was $35.12 to $64.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.